Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shield Therapeutics ( (GB:STX) ) has provided an announcement.
Shield Therapeutics announced the presentation of pediatric pharmacokinetic results for ferric maltol at the upcoming American Society of Hematology Conference. The study confirmed the suitability of ferric maltol for iron replacement in children, supporting its potential expansion to younger populations and highlighting its importance in addressing unmet medical needs in pediatric iron deficiency treatment.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on GB:STX Stock
According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical performance, indicating strong market momentum. However, significant financial weaknesses, including negative profitability and cash flow issues, weigh heavily on the score. Valuation concerns due to a negative P/E ratio and lack of dividend yield further impact the stock’s attractiveness.
To see Spark’s full report on GB:STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focusing on addressing iron deficiency through its innovative product, ACCRUFeR®/FeRACCRU® (ferric maltol). The company operates in the U.S. and has partnerships for its product in various international markets, including the UK, European Union, China, and Japan.
Average Trading Volume: 4,120,504
Technical Sentiment Signal: Buy
Current Market Cap: £72.73M
For a thorough assessment of STX stock, go to TipRanks’ Stock Analysis page.